Abstract:
PROBLEM TO BE SOLVED: To provide novel azaadamantane derivatives.SOLUTION: The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof. In the formula, Ldenotes -O- or -NR-; A denotes -Ar, -Ar-L-Aror -Ar-L-Ar; Ardenotes aryl or heteroaryl; Ardenotes aryl or monocyclic heteroaryl; Ardenotes aryl or heteroaryl; Ardenotes bicyclic heteroaryl; Ardenotes aryl or heteroaryl; Ldenotes a binding, -O -, -NR-, -CH- or -C(O)NR-; L3 denotes a binding, -O-, -NR-or -CH-; and Rdenotes hydrogen or alkyl.
Abstract translation:待解决的问题:提供新的氮杂金刚烷衍生物。 解决方案:本发明涉及式(I)的氮杂金刚烷衍生物,特别是醚或胺取代的氮杂金刚烷衍生物及其盐和前药的化合物。 在该式中,L 1 SB>表示-O-或-NR a SB> - ; A表示-Ar 1 SB>,-Ar 2 SB> -L 2 SB> 3 SB>或-Ar 4 SB> -L 3 SB> -Ar 5 SB>; Ar 1 SB>表示芳基或杂芳基; Ar 2表示芳基或单环杂芳基; Ar 3 SB>表示芳基或杂芳基; Ar 4 SB>表示双环杂芳基; Ar 5 SB>表示芳基或杂芳基; L 2 SB>表示结合,-O - , - NR a SB> - ,-CH 2 SB> - 或-C(O)NR a SB> - ; L3表示结合,-O-,-NR a SB> - 或-CH 2 SB> 并且R a SB>表示氢或烷基。 版权所有(C)2013,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide compounds useful to treat hepatitis C (HCV) infections.SOLUTION: In the compounds, the uracil or thymine derivative are linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.
Abstract:
PROBLEM TO BE SOLVED: To provide an oral suspension having no bitterness and useful for patients, such as a child and an aged, hardly swallowing a tablet. SOLUTION: A granule sufficiently tasty for use as an oral suspension is obtained by applying a complex of a new antibiotic 6-O-methylerythromycin A-carbomer (acrylic acid copolymer) represented by the formula. The crystalline form 0 solvate is its useful intermediate and a method for producing the same, a medicinal composition containing the compound and application of the composition as a therapeutic agent are provided. (Wherein, S is a solvation molecule selected from a group consisting of ethanol, isopropyl acetate, isopropanol and tetrahydrofuran.). COPYRIGHT: (C)2004,JPO
Abstract:
PROBLEM TO BE SOLVED: To provide a new erythromycin A form compound with antibacterial therapy effectiveness and its production method. SOLUTION: There are provided a new antibiotic 6-O-methylerythromycin A form 0 solvate of the formula, its production method, a medicinal composition containing the solvate, and its use as a therapeutic agent. COPYRIGHT: (C)2009,JPO&INPIT
Abstract:
The present invention relates to a novel 6- O -methylerythromycin A crystal form, a process for preparing the crystal form, and methods for using the crystal form to prepare a 6- O -methylerythromycin A crystal form II.
Abstract:
A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.
Abstract:
The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
Abstract:
The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
Abstract:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.